High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy (2024)

1. http://orcid.org/0000-0002-5922-483XRong Fan1,
2. Siru Zhao1,
3. http://orcid.org/0000-0001-5415-2024Junqi Niu2,
4. Hong Ma3,
5. http://orcid.org/0000-0002-2582-8803Qing Xie4,
6. Song Yang5,
7. Jianping Xie6,
8. http://orcid.org/0000-0003-1856-7331Xiaoguang Dou7,
9. Jia Shang8,
10. Huiying Rao9,
11. Qi Xia10,
12. Yali Liu11,
13. Yongfeng Yang12,
14. Hongbo Gao13,
15. Aimin Sun14,
16. Xieer Liang1,
17. http://orcid.org/0000-0001-9469-9366Xueru Yin1,
18. Yongfang Jiang15,
19. Yanyan Yu16,
20. Jian Sun1,
21. Nikolai V Naoumov17,
22. http://orcid.org/0000-0001-8230-8583Jinlin Hou1
23. Chronic Hepatitis B Study Consortium

1. ¹Royal College of Physicians, London, UK
2. ²Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Department of Infectious Diseases, Southern Medical University Nanfang Hospital, Guangzhou, China
3. ³Hepatology Unit, No. 1 Hospital affiliated to Jilin University, Changchun, China
4. ⁴Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
5. ⁵Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6. ⁶Beijing Ditan Hospital, Capital Medical University, Beijing, China
7. ⁷Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China
8. ⁸Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China
9. ⁹Henan Provincial People's Hospital, Zhengzhou, China
10. ¹⁰Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China
11. ¹¹State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
12. ¹²Beijing Youan Hospital, Capital Medical University, Beijing, China
13. ¹³The Second Hospital of Nanjing, Nanjing, China
14. ¹⁴8th People's Hospital, Guangzhou, China
15. ¹⁵Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China
16. ¹⁶Liver Disease Research Center, the Second Xiangya Hospital, Central South University, Changsha, China
17. ¹⁷Department of Infectious Diseases, First Hospital of Peking University, Beijing, China

1. Correspondence to Professor Jinlin Hou, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; jlhousmu{at}163.com; Professor Rong Fan, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; rongfansmu{at}163.com

• CHRONIC HEPATITIS
• HEPATITIS B

• CHRONIC HEPATITIS
• HEPATITIS B

Footnotes

• RF and SZ are joint first authors.

• Collaborators Chronic Hepatitis B Study Consortium for detailed list, please see online supplemental material.

• Contributors JH, RF and NVN contributed to the conception and design of the study. JH and RF coordinated the study. RF, JN, HM, QXie, SY, JX, XD, JShang, HR, QXia, YL, YYang, HG, AS, XL, XY, YJ, YYu, JSun and the other members from chronic Hepatitis B Study Consortium (For detailed list, please see online supplemental material) acquired the data. JH, RF and SZ did the statistical analysis, interpreted the data and verified the underlying data. JH, RF, NVN and SZ prepared the manuscript. All authors contributed to the discissions and interpretation of study results, approved the final manuscript and had final responsibility for the decision to submit for publication. JH and RF are the guarantors.

• Funding This work was supported by National Key Research and Development Program of China (2022YFC2303600, 2022YFC2304800), the National Natural Science Foundation of China (82170610) and GuangDong Basic and Applied Basic Research Foundation (2023A1515011211).

• Competing interests JH received consulting fees from GlaxoSmithKline, Gilead Sciences and a Grant from Roche. NVN is an independent advisor to HistoIndex and a member of the scientific advisory board for InSphero. The other authors declare no conflicts of interest that pertain to this work.

• Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.